首页 > 最新文献

Clinical & Translational Immunology最新文献

英文 中文
Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes 新型流感衍生 HLA-B*18:01 限制性表位的特征描述
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-05-10 DOI: 10.1002/cti2.1509
Samuel Liwei Leong, Lawton Murdolo, Janesha C Maddumage, Marios Koutsakos, Katherine Kedzierska, Anthony W Purcell, Stephanie Gras, Emma J Grant

Objectives

Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.

Methods

Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.

Results

Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01+ individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP219 peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.

Conclusion

Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.

尽管有疫苗可用,但季节性流感病毒每年仍会导致大约 65 万人死亡。CD8+ T 细胞通常能识别来自内部结构和非结构性流感蛋白的流感衍生肽,是未来疫苗设计的一个有吸引力的途径,因为它们能降低感染不同流感病毒株后的疾病严重程度。CD8+ T 细胞能识别由高度多态的人类白细胞抗原 I 类分子(HLA-I)呈现的肽。每种 HLA-I 变体都有不同的肽结合偏好,这对设计能在广泛人群中引起 CD8+ T 细胞反应的疫苗构成了重大障碍。因此,要合理设计 CD8+ T 细胞介导的疫苗,就必须鉴定出限制于一系列不同 HLA 分子的高免疫原性肽。 方法 在此,我们评估了最近发表的六种新型流感衍生肽的免疫原性,这些肽是通过质谱分析鉴定的,并预测能与流行的 HLA-B*18:01 分子结合。 结果 我们使用 CD8+ T 细胞活化试验和蛋白质生物化学方法表明,3/6 种新型多肽在几个 HLA-B*18:01+ 的个体中具有免疫原性,并证实了它们的 HLA-B*18:01 限制。随后,我们比较了 CD8+ T 细胞对之前发现的高免疫原性 HLA-B*18:01 限制性 NP219 肽的反应。通过 X 射线晶体学,我们首次解析了 HLA-B*18:01 呈现免疫原性流感衍生肽的晶体结构。最后,我们剖析了首个针对 HLA-B*18:01 限制性病原体衍生肽的特异性 TCR 反应谱,确定了针对四种肽中每一种肽的私有和限制性反应谱。 结论 总的来说,这些新型免疫原性多肽的特征描述提供了更多的 HLA-B*18:01 限制性疫苗靶标,这些靶标来自基质蛋白 1,也可能来自流感病毒的非结构蛋白和 RNA 聚合酶催化亚基。
{"title":"Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes","authors":"Samuel Liwei Leong,&nbsp;Lawton Murdolo,&nbsp;Janesha C Maddumage,&nbsp;Marios Koutsakos,&nbsp;Katherine Kedzierska,&nbsp;Anthony W Purcell,&nbsp;Stephanie Gras,&nbsp;Emma J Grant","doi":"10.1002/cti2.1509","DOIUrl":"https://doi.org/10.1002/cti2.1509","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8<sup>+</sup> T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8<sup>+</sup> T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8<sup>+</sup> T cell responses across broad populations. Consequently, the rational design of a CD8<sup>+</sup> T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Using CD8<sup>+</sup> T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01<sup>+</sup> individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8<sup>+</sup> T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP<sub>219</sub> peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 5","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1509","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of extremely preterm birth on cytokine and chemokine responses induced by T-cell activation during infancy 极早产对婴儿期 T 细胞激活诱导的细胞因子和趋化因子反应的影响
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-05-10 DOI: 10.1002/cti2.1510
Dhanapal Govindaraj, Georg Bach Jensen, Khaleda Rahman Qazi, Eva Sverremark-Ekström, Thomas Abrahamsson, Maria C Jenmalm

Objectives

Extremely preterm (EPT; gestational week < 28 + 0, < 1000 g) neonates are vulnerable to infections and necrotising enterocolitis, important contributors to mortality and morbidity. However, knowledge regarding their immune maturation remains limited. We here investigated the longitudinal development of functional T-cell capacity in EPT infants.

Methods

Peripheral blood mononuclear cells were isolated at 14th and 28th day (D) and at gestational week 36 + 0 (Gw36) from EPT infants, participated in a randomised, double-blind, placebo-controlled study of Lactobacillus reuteri DSM 17938 probiotic supplementation. Blood collected from 25 full-term (FT) infants at D14 was used as control. The secretion of immune mediators was determined through comprehensive Luminex panels after stimulation with human T-cell activator CD3/CD28 beads.

Results

The levels of many mediators were low in EPT infants at D14, whereas the secretion of several chemokines was higher in EPT than in FT infants. Furthermore, Th2:Th1 cytokine ratios were higher in EPT than in FT infants. Progressively elevated secretion of, for example, IFN-γ, TNF and IL-17A in EPT infants was observed from D14 to D28 and then at Gw36. Elevated levels were observed for many proinflammatory mediators at D28. Probiotic supplementation or perinatal factors (e.g. clinical chorioamnionitis, preeclampsia and delivery mode) did not influence the cytokine and chemokine responses.

Conclusions

Immune mediators induced by T-cell activation in EPT infants were mainly reduced at D14 and Th2 skewed compared to those in FT infants, but mostly recovered at Gw36, indicating immune maturation. Increased proinflammatory responses at D28 may be related to the heightened risk of severe immune-associated complications seen in EPT infants.

目的 极早产(EPT;孕周 28 + 0,体重 1000 克)新生儿很容易受到感染和坏死性小肠结肠炎的侵袭,这是导致死亡和发病的重要因素。然而,有关他们免疫成熟的知识仍然有限。我们在此研究了 EPT 婴儿 T 细胞功能的纵向发展。 方法 在 EPT 婴儿出生后第 14 天和第 28 天(D)以及妊娠 36+0 周(Gw36)分离出外周血单核细胞,这些婴儿参加了一项关于补充 Lactobacillus reuteri DSM 17938 益生菌的随机、双盲、安慰剂对照研究。25 名足月(FT)婴儿在出生后 14 天采集的血液作为对照。在使用人 T 细胞激活剂 CD3/CD28 微珠刺激后,通过 Luminex 综合检测板测定免疫介质的分泌情况。 结果 EPT 婴儿在 14 岁时许多介质的水平较低,而几种趋化因子在 EPT 婴儿中的分泌高于 FT 婴儿。此外,EPT 婴儿的 Th2:Th1 细胞因子比率高于 FT 婴儿。EPT婴儿的IFN-γ、TNF和IL-17A等细胞因子的分泌量从D14到D28,然后到Gw36逐渐升高。D28时,许多促炎介质水平升高。益生菌补充剂或围产期因素(如临床绒毛膜羊膜炎、先兆子痫和分娩方式)并不影响细胞因子和趋化因子的反应。 结论 与FT婴儿相比,EPT婴儿T细胞活化诱导的免疫介质主要在D14时减少,并偏向Th2,但在Gw36时大部分恢复,表明免疫成熟。EPT婴儿出现严重免疫相关并发症的风险增加可能与D28时促炎反应增加有关。
{"title":"Effects of extremely preterm birth on cytokine and chemokine responses induced by T-cell activation during infancy","authors":"Dhanapal Govindaraj,&nbsp;Georg Bach Jensen,&nbsp;Khaleda Rahman Qazi,&nbsp;Eva Sverremark-Ekström,&nbsp;Thomas Abrahamsson,&nbsp;Maria C Jenmalm","doi":"10.1002/cti2.1510","DOIUrl":"https://doi.org/10.1002/cti2.1510","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Extremely preterm (EPT; gestational week &lt; 28 + 0, &lt; 1000 g) neonates are vulnerable to infections and necrotising enterocolitis, important contributors to mortality and morbidity. However, knowledge regarding their immune maturation remains limited. We here investigated the longitudinal development of functional T-cell capacity in EPT infants.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Peripheral blood mononuclear cells were isolated at 14th and 28th day (D) and at gestational week 36 + 0 (Gw36) from EPT infants, participated in a randomised, double-blind, placebo-controlled study of <i>Lactobacillus reuteri</i> DSM 17938 probiotic supplementation. Blood collected from 25 full-term (FT) infants at D14 was used as control. The secretion of immune mediators was determined through comprehensive Luminex panels after stimulation with human T-cell activator CD3/CD28 beads.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The levels of many mediators were low in EPT infants at D14, whereas the secretion of several chemokines was higher in EPT than in FT infants. Furthermore, Th2:Th1 cytokine ratios were higher in EPT than in FT infants. Progressively elevated secretion of, for example, IFN-γ, TNF and IL-17A in EPT infants was observed from D14 to D28 and then at Gw36. Elevated levels were observed for many proinflammatory mediators at D28. Probiotic supplementation or perinatal factors (e.g. clinical chorioamnionitis, preeclampsia and delivery mode) did not influence the cytokine and chemokine responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Immune mediators induced by T-cell activation in EPT infants were mainly reduced at D14 and Th2 skewed compared to those in FT infants, but mostly recovered at Gw36, indicating immune maturation. Increased proinflammatory responses at D28 may be related to the heightened risk of severe immune-associated complications seen in EPT infants.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 5","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1510","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintenance of caecal homeostasis by diverse adaptive immune cells in the rhesus macaque 猕猴的多种适应性免疫细胞维持盲肠稳态
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-05-02 DOI: 10.1002/cti2.1508
Xaquin Castro Dopico, Mariia Guryleva, Marco Mandolesi, Martin Corcoran, Jonathan M Coquet, Ben Murrell, Gunilla B Karlsson Hedestam

Objectives

The caecum bridges the small and large intestine and plays a front-line role in discriminating gastrointestinal antigens. Although dysregulated in acute and chronic conditions, the tissue is often overlooked immunologically.

Methods

To address this issue, we applied single-cell transcriptomic-V(D)J sequencing to FACS-isolated CD45+ caecal patch/lamina propria leukocytes from a healthy (5-year-old) female rhesus macaque ex vivo and coupled these data to VDJ deep sequencing reads from haematopoietic tissues.

Results

We found caecal NK cells and ILC3s to co-exist with a spectrum of effector T cells partially derived from SOX4+ recent thymic emigrants. Tolerogenic Vγ8Vδ1-T cells, plastic CD4+ T helper cells and GZMK+EOMES+ and TMIGD2+ tissue-resident memory CD8+ T cells were present and differed metabolically. An IL13+GATA3+ Th2 subset expressing eicosanoid pathway enzymes was accompanied by IL1RL1+GATA3+ regulatory T cells and a minor proportion of IgE+ plasma cells (PCs), illustrating tightly regulated type 2 immunity devoid of ILC2s. In terms of B lymphocyte lineages, caecal patch antigen-presenting memory B cells sat alongside germinal centre cells undergoing somatic hypermutation and differentiation into IGF1+ PCs. Prototypic gene expression signatures decreased across PC clusters, and notably, expanded IgA clonotypes could be traced in VDJ deep sequencing reads from additional compartments, including the bone marrow, supporting that these cells contribute a steady stream of systemic antibodies.

Conclusions

The data advance our understanding of caecal immunological function, revealing processes involved in barrier maintenance and molecular networks relevant to disease.

目的 盲肠是连接小肠和大肠的桥梁,在分辨胃肠道抗原方面发挥着前线作用。虽然该组织在急性和慢性疾病中失调,但在免疫学上却经常被忽视。 方法 为了解决这个问题,我们应用单细胞转录组-V(D)J 测序技术检测了从一只健康(5 岁)雌性恒河猴体内分离出的 CD45+ 盲肠斑块/固有膜白细胞,并将这些数据与来自造血组织的 VDJ 深度测序读数结合起来。 结果 我们发现盲肠 NK 细胞和 ILC3s 与效应 T 细胞谱系共存,部分效应 T 细胞来自 SOX4+ 近期胸腺移民。耐受性 Vγ8Vδ1-T 细胞、可塑性 CD4+ T 辅助细胞以及 GZMK+EOMES+ 和 TMIGD2+ 组织驻留记忆 CD8+ T 细胞都存在,并且在新陈代谢方面存在差异。表达二十碳烷途径酶的 IL13+GATA3+ Th2 亚群伴随着 IL1RL1+GATA3+ 调节性 T 细胞和小部分 IgE+ 浆细胞(PCs),这说明第二型免疫受到严格调控,不存在 ILC2s。在 B 淋巴细胞系方面,盲肠补片抗原递呈记忆 B 细胞与生殖中心细胞并存,后者正在经历体细胞超突变并分化为 IGF1+ PCs。各 PC 群的原型基因表达特征均有所下降,值得注意的是,从包括骨髓在内的其他分区的 VDJ 深度测序读数中可追踪到扩大的 IgA 克隆型,这支持了这些细胞可源源不断地产生全身抗体。 结论 这些数据增进了我们对盲肠免疫功能的了解,揭示了盲肠屏障维持过程以及与疾病相关的分子网络。
{"title":"Maintenance of caecal homeostasis by diverse adaptive immune cells in the rhesus macaque","authors":"Xaquin Castro Dopico,&nbsp;Mariia Guryleva,&nbsp;Marco Mandolesi,&nbsp;Martin Corcoran,&nbsp;Jonathan M Coquet,&nbsp;Ben Murrell,&nbsp;Gunilla B Karlsson Hedestam","doi":"10.1002/cti2.1508","DOIUrl":"https://doi.org/10.1002/cti2.1508","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The caecum bridges the small and large intestine and plays a front-line role in discriminating gastrointestinal antigens. Although dysregulated in acute and chronic conditions, the tissue is often overlooked immunologically.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To address this issue, we applied single-cell transcriptomic-V(D)J sequencing to FACS-isolated CD45<sup>+</sup> caecal patch/lamina propria leukocytes from a healthy (5-year-old) female rhesus macaque <i>ex vivo</i> and coupled these data to VDJ deep sequencing reads from haematopoietic tissues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found caecal NK cells and ILC3s to co-exist with a spectrum of effector T cells partially derived from <i>SOX4</i><sup>+</sup> recent thymic emigrants. Tolerogenic Vγ8Vδ1-T cells, plastic CD4<sup>+</sup> T helper cells and <i>GZMK</i><sup>+</sup><i>EOMES</i><sup>+</sup> and <i>TMIGD2</i><sup>+</sup> tissue-resident memory CD8<sup>+</sup> T cells were present and differed metabolically. An <i>IL13</i><sup>+</sup><i>GATA3</i><sup>+</sup> Th<sub>2</sub> subset expressing eicosanoid pathway enzymes was accompanied by <i>IL1RL1</i><sup>+</sup><i>GATA3</i><sup>+</sup> regulatory T cells and a minor proportion of IgE<sup>+</sup> plasma cells (PCs), illustrating tightly regulated type 2 immunity devoid of ILC2s. In terms of B lymphocyte lineages, caecal patch antigen-presenting memory B cells sat alongside germinal centre cells undergoing somatic hypermutation and differentiation into <i>IGF1</i><sup>+</sup> PCs. Prototypic gene expression signatures decreased across PC clusters, and notably, expanded IgA clonotypes could be traced in VDJ deep sequencing reads from additional compartments, including the bone marrow, supporting that these cells contribute a steady stream of systemic antibodies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The data advance our understanding of caecal immunological function, revealing processes involved in barrier maintenance and molecular networks relevant to disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 5","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140818974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimisation of a primary human CAR-NK cell manufacturing pipeline 优化原代人类 CAR-NK 细胞生产流水线
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-05-02 DOI: 10.1002/cti2.1507
Aline Pfefferle, Julian Contet, Kahlia Wong, Charlotte Chen, Els Verhoeyen, Chloe K Slichter, Kimberly S Schluns, Joseph Cursons, Richard Berry, Iva Nikolic, Jai Rautela, Nicholas D Huntington

Objectives

Autologous chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies achieves long-term disease remission in a high fraction of patients and has triggered intense research into translating this successful approach into additional cancer types. However, the complex logistics involved in autologous CAR-T manufacturing, the compromised fitness of patient-derived T cells, the high rates of serious toxicities and the overall cost involved with product manufacturing and hospitalisation have driven innovation to overcome such hurdles. One alternative approach is the use of allogeneic natural killer (NK) cells as a source for CAR-NK cell therapy. However, this source has traditionally faced numerous manufacturing challenges.

Methods

To address this, we have developed an optimised expansion and transduction protocol for primary human NK cells primed for manufacturing scaling and clinical evaluation. We have performed an in-depth comparison of primary human NK cell sources as a starting material by characterising their phenotype, functionality, expansion potential and transduction efficiency at crucial timepoints of our CAR-NK manufacturing pipeline.

Results

We identified adult peripheral blood-derived NK cells to be the superior source for generating a CAR-NK cell product because of a higher maximum yield of CAR-expressing NK cells combined with potent natural, as well as CAR-mediated anti-tumor effector functions.

Conclusions

Our optimised manufacturing pipeline dramatically improves lentiviral transduction efficiency of primary human NK cells. We conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make peripheral blood-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

目标 B 细胞恶性肿瘤的自体嵌合抗原受体(CAR)T 细胞疗法能使大量患者的疾病得到长期缓解,并引发了将这一成功疗法转化为其他癌症类型的深入研究。然而,自体 CAR-T 生产所涉及的复杂物流、患者来源 T 细胞的适配性、严重毒性反应的高发率以及产品生产和住院所涉及的总体成本,都推动了克服这些障碍的创新。一种替代方法是使用异体自然杀伤(NK)细胞作为 CAR-NK 细胞疗法的来源。然而,这种来源在传统上面临着许多制造难题。 方法 为了解决这个问题,我们为原代人类 NK 细胞开发了一套优化的扩增和转导方案,以便进行规模化生产和临床评估。我们对作为起始材料的原代人 NK 细胞来源进行了深入比较,在 CAR-NK 生产流水线的关键时间点对其表型、功能、扩增潜力和转导效率进行了鉴定。 结果 我们发现成人外周血来源的 NK 细胞是生产 CAR-NK 细胞产品的上佳来源,因为它们具有更高的 CAR 表达 NK 细胞最大产量,同时具有强大的天然和 CAR 介导的抗肿瘤效应功能。 结论 我们优化的生产流水线显著提高了原代人类 NK 细胞的慢病毒转导效率。我们的结论是,转导前后的指数扩增和高靶向细胞毒性使外周血来源的 NK 细胞成为一种可行且有吸引力的 CAR-NK 细胞产品,可用于临床。
{"title":"Optimisation of a primary human CAR-NK cell manufacturing pipeline","authors":"Aline Pfefferle,&nbsp;Julian Contet,&nbsp;Kahlia Wong,&nbsp;Charlotte Chen,&nbsp;Els Verhoeyen,&nbsp;Chloe K Slichter,&nbsp;Kimberly S Schluns,&nbsp;Joseph Cursons,&nbsp;Richard Berry,&nbsp;Iva Nikolic,&nbsp;Jai Rautela,&nbsp;Nicholas D Huntington","doi":"10.1002/cti2.1507","DOIUrl":"https://doi.org/10.1002/cti2.1507","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Autologous chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies achieves long-term disease remission in a high fraction of patients and has triggered intense research into translating this successful approach into additional cancer types. However, the complex logistics involved in autologous CAR-T manufacturing, the compromised fitness of patient-derived T cells, the high rates of serious toxicities and the overall cost involved with product manufacturing and hospitalisation have driven innovation to overcome such hurdles. One alternative approach is the use of allogeneic natural killer (NK) cells as a source for CAR-NK cell therapy. However, this source has traditionally faced numerous manufacturing challenges.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To address this, we have developed an optimised expansion and transduction protocol for primary human NK cells primed for manufacturing scaling and clinical evaluation. We have performed an in-depth comparison of primary human NK cell sources as a starting material by characterising their phenotype, functionality, expansion potential and transduction efficiency at crucial timepoints of our CAR-NK manufacturing pipeline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified adult peripheral blood-derived NK cells to be the superior source for generating a CAR-NK cell product because of a higher maximum yield of CAR-expressing NK cells combined with potent natural, as well as CAR-mediated anti-tumor effector functions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our optimised manufacturing pipeline dramatically improves lentiviral transduction efficiency of primary human NK cells. We conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make peripheral blood-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 5","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1507","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140818975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder 几丁质酶 3 样 1 的表达与膀胱尿路上皮癌的淋巴转移和预后有关
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-04-15 DOI: 10.1002/cti2.1505
Bo Wang, Ke Chen, Mingchao Gao, Xi Sun, Wang He, Junyu Chen, Wenjuan Yang, Tenghao Yang, Haide Qin, Honglian Ruan, Hao Huang, Tianxin Lin, Jian Huang

Objectives

Lymphatic metastasis, an early stage of the metastasis process, is associated with adverse clinical outcomes in urothelial carcinoma of the bladder (UCB). However, the role of inflammation in triggering lymphatic metastasis remains unclear.

Methods

We employed an RNA-sequencing cohort (n = 50) from Sun Yat-Sen Memorial Hospital (SYMH) to identify the most highly upregulated inflammatory gene associated with lymphatic metastasis. Using immunohistochemistry and immunofluorescence analyses, we validated the association of the identified molecule with clinical features and prognosis in an independent UCB cohort (n = 244) from SYMH. We also analysed TCGA-BLCA cohort (n = 408) to identify its potential biological pathways and immune landscape.

Results

In our study, chitinase 3-like 1 (CHI3L1) emerged as a significantly overexpressed proinflammatory mediator in UCB tissues with lymphatic metastasis compared to those without lymphatic metastasis (81.1% vs. 47.8%, P < 0.001). Within UCB tissues, CHI3L1 was expressed in both stromal cells (52.8%) and tumor cells (7.3%). Moreover, CHI3L1+ stromal cells, but not tumor cells, exhibited independent prognostic significance for both overall survival (P < 0.001) and recurrence-free survival (P = 0.006). CHI3L1+ stromal cells were positively associated with D2-40+ lymphatic vessel density (P < 0.001) and the immunosuppressive PD-L1/PD-1/CD8 axis in UCB tissues (all P < 0.05). A bioinformatics analysis also identified a positive association between CHI3L1 expression and lymphangiogenesis or immunosuppression pathways.

Conclusion

Our study established a clear association between stromal CHI3L1 expression and lymphatic metastasis, suggesting that stromal CHI3L1 expression is a potential prognostic marker for bladder cancer patients.

目的 淋巴转移是转移过程的早期阶段,与膀胱尿路上皮癌(UCB)的不良临床预后有关。然而,炎症在引发淋巴转移中的作用仍不清楚。 方法 我们利用中山大学孙逸仙纪念医院(SYMH)的RNA测序队列(n = 50)来确定与淋巴转移相关的最高度上调的炎症基因。通过免疫组织化学和免疫荧光分析,我们在中山大学孙逸仙纪念医院的独立 UCB 队列(n = 244)中验证了所发现的分子与临床特征和预后的关联。我们还分析了 TCGA-BLCA 队列(n = 408),以确定其潜在的生物通路和免疫格局。 结果 在我们的研究中,与无淋巴转移的 UCB 组织相比,几丁质酶 3-like 1 (CHI3L1) 在有淋巴转移的 UCB 组织中是一个显著过表达的促炎介质(81.1% vs. 47.8%,P < 0.001)。在 UCB 组织中,CHI3L1 在基质细胞(52.8%)和肿瘤细胞(7.3%)中均有表达。此外,CHI3L1+基质细胞(而非肿瘤细胞)对总生存期(P < 0.001)和无复发生存期(P = 0.006)具有独立的预后意义。CHI3L1+ 基质细胞与 D2-40+ 淋巴管密度(P <;0.001)和 UCB 组织中的免疫抑制 PD-L1/PD-1/CD8 轴(均为 P <;0.05)呈正相关。生物信息学分析还发现 CHI3L1 表达与淋巴管生成或免疫抑制通路之间存在正相关。 结论 我们的研究在基质 CHI3L1 表达与淋巴转移之间建立了明确的关联,表明基质 CHI3L1 表达是膀胱癌患者潜在的预后标志物。
{"title":"Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder","authors":"Bo Wang,&nbsp;Ke Chen,&nbsp;Mingchao Gao,&nbsp;Xi Sun,&nbsp;Wang He,&nbsp;Junyu Chen,&nbsp;Wenjuan Yang,&nbsp;Tenghao Yang,&nbsp;Haide Qin,&nbsp;Honglian Ruan,&nbsp;Hao Huang,&nbsp;Tianxin Lin,&nbsp;Jian Huang","doi":"10.1002/cti2.1505","DOIUrl":"https://doi.org/10.1002/cti2.1505","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Lymphatic metastasis, an early stage of the metastasis process, is associated with adverse clinical outcomes in urothelial carcinoma of the bladder (UCB). However, the role of inflammation in triggering lymphatic metastasis remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We employed an RNA-sequencing cohort (<i>n</i> = 50) from Sun Yat-Sen Memorial Hospital (SYMH) to identify the most highly upregulated inflammatory gene associated with lymphatic metastasis. Using immunohistochemistry and immunofluorescence analyses, we validated the association of the identified molecule with clinical features and prognosis in an independent UCB cohort (<i>n</i> = 244) from SYMH. We also analysed TCGA-BLCA cohort (<i>n</i> = 408) to identify its potential biological pathways and immune landscape.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In our study, chitinase 3-like 1 (CHI3L1) emerged as a significantly overexpressed proinflammatory mediator in UCB tissues with lymphatic metastasis compared to those without lymphatic metastasis (81.1% vs. 47.8%, <i>P</i> &lt; 0.001). Within UCB tissues, CHI3L1 was expressed in both stromal cells (52.8%) and tumor cells (7.3%). Moreover, CHI3L1<sup>+</sup> stromal cells, but not tumor cells, exhibited independent prognostic significance for both overall survival (<i>P</i> &lt; 0.001) and recurrence-free survival (<i>P</i> = 0.006). CHI3L1<sup>+</sup> stromal cells were positively associated with D2-40<sup>+</sup> lymphatic vessel density (<i>P</i> &lt; 0.001) and the immunosuppressive PD-L1/PD-1/CD8 axis in UCB tissues (all <i>P</i> &lt; 0.05). A bioinformatics analysis also identified a positive association between CHI3L1 expression and lymphangiogenesis or immunosuppression pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study established a clear association between stromal CHI3L1 expression and lymphatic metastasis, suggesting that stromal CHI3L1 expression is a potential prognostic marker for bladder cancer patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 4","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140553107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2-infected human airway epithelial cell cultures uniquely lack interferon and immediate early gene responses caused by other coronaviruses 感染了 SARS-CoV-2 的人类气道上皮细胞培养物独特地缺乏由其他冠状病毒引起的干扰素和即刻早期基因反应
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-04-15 DOI: 10.1002/cti2.1503
Ying Wang, Melissa Thaler, Clarisse Salgado-Benvindo, Nathan Ly, Anouk A Leijs, Dennis K Ninaber, Philip M Hansbro, Fia Boedijono, Martijn J van Hemert, Pieter S Hiemstra, Anne M van der Does, Alen Faiz

Objectives

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of a class of highly pathogenic coronaviruses. The large family of coronaviruses, however, also includes members that cause only mild symptoms, like human coronavirus-229E (HCoV-229E) or OC43 (HCoV-OC43). Unravelling how molecular (and cellular) pathophysiology differs between highly and low pathogenic coronaviruses is important for the development of therapeutic strategies.

Methods

Here, we analysed the transcriptome of primary human bronchial epithelial cells (PBEC), differentiated at the air–liquid interface (ALI) after infection with SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome (MERS)-CoV and HCoV-229E using bulk RNA sequencing.

Results

ALI-PBEC were efficiently infected by all viruses, and SARS-CoV, MERS-CoV and HCoV-229E infection resulted in a largely similar transcriptional response. The response to SARS-CoV-2 infection differed markedly as it uniquely lacked the increase in expression of immediate early genes, including FOS, FOSB and NR4A1 that was observed with all other coronaviruses. This finding was further confirmed in publicly available experimental and clinical datasets. Interfering with NR4A1 signalling in Calu-3 lung epithelial cells resulted in a 100-fold reduction in extracellular RNA copies of SARS-CoV-2 and MERS-CoV, suggesting an involvement in virus replication. Furthermore, a lack in induction of interferon-related gene expression characterised the main difference between the highly pathogenic coronaviruses and low pathogenic viruses HCoV-229E and HCoV-OC43.

Conclusion

Our results demonstrate a previously unknown suppression of a host response gene set by SARS-CoV-2 and confirm a difference in interferon-related gene expression between highly pathogenic and low pathogenic coronaviruses.

目标 严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)是一类高致病性冠状病毒。然而,冠状病毒大家族中也有一些只引起轻微症状的成员,如人类冠状病毒-229E(HCoV-229E)或 OC43(HCoV-OC43)。了解高致病性冠状病毒和低致病性冠状病毒的分子(和细胞)病理生理学有何不同对于制定治疗策略非常重要。 方法 在此,我们使用大容量 RNA 测序分析了原代人支气管上皮细胞(PBEC)的转录组,这些细胞在感染 SARS-CoV-2、SARS-CoV、中东呼吸综合征(MERS)-CoV 和 HCoV-229E 后在气液界面(ALI)分化。 结果 ALI-PBEC 能有效感染所有病毒,SARS-CoV、MERS-CoV 和 HCoV-229E 感染导致的转录反应基本相似。感染 SARS-CoV-2 后的反应则明显不同,因为它独特地缺乏在所有其他冠状病毒中观察到的即时早期基因(包括 FOS、FOSB 和 NR4A1)表达的增加。这一发现在公开的实验和临床数据集中得到了进一步证实。干扰 Calu-3 肺上皮细胞中的 NR4A1 信号可使 SARS-CoV-2 和 MERS-CoV 的胞外 RNA 拷贝减少 100 倍,这表明 NR4A1 参与了病毒复制。此外,高致病性冠状病毒与低致病性病毒 HCoV-229E 和 HCoV-OC43 之间的主要区别在于缺乏对干扰素相关基因表达的诱导。 结论 我们的研究结果表明,SARS-CoV-2 对宿主反应基因集的抑制作用以前不为人知,并证实了高致病性冠状病毒和低致病性冠状病毒之间在干扰素相关基因表达方面的差异。
{"title":"SARS-CoV-2-infected human airway epithelial cell cultures uniquely lack interferon and immediate early gene responses caused by other coronaviruses","authors":"Ying Wang,&nbsp;Melissa Thaler,&nbsp;Clarisse Salgado-Benvindo,&nbsp;Nathan Ly,&nbsp;Anouk A Leijs,&nbsp;Dennis K Ninaber,&nbsp;Philip M Hansbro,&nbsp;Fia Boedijono,&nbsp;Martijn J van Hemert,&nbsp;Pieter S Hiemstra,&nbsp;Anne M van der Does,&nbsp;Alen Faiz","doi":"10.1002/cti2.1503","DOIUrl":"https://doi.org/10.1002/cti2.1503","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of a class of highly pathogenic coronaviruses. The large family of coronaviruses, however, also includes members that cause only mild symptoms, like human coronavirus-229E (HCoV-229E) or OC43 (HCoV-OC43). Unravelling how molecular (and cellular) pathophysiology differs between highly and low pathogenic coronaviruses is important for the development of therapeutic strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Here, we analysed the transcriptome of primary human bronchial epithelial cells (PBEC), differentiated at the air–liquid interface (ALI) after infection with SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome (MERS)-CoV and HCoV-229E using bulk RNA sequencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ALI-PBEC were efficiently infected by all viruses, and SARS-CoV, MERS-CoV and HCoV-229E infection resulted in a largely similar transcriptional response. The response to SARS-CoV-2 infection differed markedly as it uniquely lacked the increase in expression of immediate early genes, including <i>FOS</i>, <i>FOSB</i> and <i>NR4A1</i> that was observed with all other coronaviruses. This finding was further confirmed in publicly available experimental and clinical datasets. Interfering with NR4A1 signalling in Calu-3 lung epithelial cells resulted in a 100-fold reduction in extracellular RNA copies of SARS-CoV-2 and MERS-CoV, suggesting an involvement in virus replication. Furthermore, a lack in induction of interferon-related gene expression characterised the main difference between the highly pathogenic coronaviruses and low pathogenic viruses HCoV-229E and HCoV-OC43.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results demonstrate a previously unknown suppression of a host response gene set by SARS-CoV-2 and confirm a difference in interferon-related gene expression between highly pathogenic and low pathogenic coronaviruses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 4","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1503","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140553106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies 嵌合抗原受体 T 细胞驶入自身免疫性疾病疗法的快车道
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-04-12 DOI: 10.1002/cti2.1502
Zhoujie Ding, David Tarlinton

In this commentary, we highlight recent studies demonstrating the feasibility and promise of chimeric antigen receptor (CAR) T-cell therapy in treating a number of autoimmune disorders including systemic lupus erythematosus and compare CAR T cells to other therapies aimed at depleting B-lineage cells in treating such diseases.

在这篇评论中,我们重点介绍了最近的一些研究,这些研究证明了嵌合抗原受体(CAR)T细胞疗法在治疗包括系统性红斑狼疮在内的多种自身免疫性疾病方面的可行性和前景,并将CAR T细胞与其他旨在消耗B系细胞以治疗此类疾病的疗法进行了比较。
{"title":"Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies","authors":"Zhoujie Ding,&nbsp;David Tarlinton","doi":"10.1002/cti2.1502","DOIUrl":"https://doi.org/10.1002/cti2.1502","url":null,"abstract":"<p>In this commentary, we highlight recent studies demonstrating the feasibility and promise of chimeric antigen receptor (CAR) T-cell therapy in treating a number of autoimmune disorders including systemic lupus erythematosus and compare CAR T cells to other therapies aimed at depleting B-lineage cells in treating such diseases.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 4","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1502","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140546872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD177 drives the transendothelial migration of Treg cells enriched in human colorectal cancer CD177 驱动人类结直肠癌中富集的 Treg 细胞跨内皮迁移
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-04-09 DOI: 10.1002/cti2.1506
Shouyu Ke, Yi Lei, Yixian Guo, Feng Xie, Yimeng Yu, Haigang Geng, Yiqing Zhong, Danhua Xu, Xu Liu, Fengrong Yu, Xiang Xia, Zizhen Zhang, Chunchao Zhu, Wei Ling, Bin Li, Wenyi Zhao

Objectives

Regulatory T (Treg) cells regulate immunity in autoimmune diseases and cancers. However, immunotherapies that target tumor-infiltrating Treg cells often induce unwanted immune responses and tissue inflammation. Our research focussed on exploring the expression pattern of CD177 in tumor-infiltrating Treg cells with the aim of identifying a potential target that can enhance immunotherapy effectiveness.

Methods

Single-cell RNA sequencing (scRNA-seq) data and survival data were obtained from public databases. Twenty-one colorectal cancer patient samples, including fresh tumor tissues, peritumoral tissues and peripheral blood mononuclear cells (PBMCs), were analysed using flow cytometry. The transendothelial activity of CD177+ Treg cells was substantiated using in vitro experiments.

Results

ScRNA-seq and flow cytometry results indicated that CD177 was exclusively expressed in intratumoral Treg cells. CD177+ Treg cells exhibited greater activation status and expressed elevated Treg cell canonical markers and immune checkpoint molecules than CD177 Treg cells. We further discovered that both intratumoral CD177+ Treg cells and CD177-overexpressing induced Treg (iTreg) cells had lower levels of PD-1 than their CD177 counterparts. Moreover, CD177 overexpression significantly enhanced the transendothelial migration of Treg cells in vitro.

Conclusions

These results demonstrated that Treg cells with higher CD177 levels exhibited an enhanced activation status and transendothelial migration capacity. Our findings suggest that CD177 may serve as an immunotherapeutic target and that overexpression of CD177 may improve the efficacy of chimeric antigen receptor T (CAR-T) cell therapy.

目的 调节性 T(Treg)细胞在自身免疫性疾病和癌症中调节免疫。然而,针对肿瘤浸润 Treg 细胞的免疫疗法往往会诱发不必要的免疫反应和组织炎症。我们的研究重点是探索 CD177 在肿瘤浸润 Treg 细胞中的表达模式,目的是确定一个能提高免疫疗法效果的潜在靶点。 方法 从公共数据库中获取单细胞 RNA 测序(scRNA-seq)数据和生存数据。利用流式细胞术分析了 21 例结直肠癌患者样本,包括新鲜肿瘤组织、瘤周组织和外周血单核细胞(PBMCs)。体外实验证实了 CD177+ Treg 细胞的跨内皮细胞活性。 结果 ScRNA-seq 和流式细胞术结果表明,CD177 只在瘤内 Treg 细胞中表达。与 CD177- Treg 细胞相比,CD177+ Treg 细胞表现出更高的活化状态,并表达出更高的 Treg 细胞典型标志物和免疫检查点分子。我们进一步发现,瘤内 CD177+ Treg 细胞和 CD177 高表达诱导 Treg(iTreg)细胞的 PD-1 水平都低于 CD177- Treg 细胞。此外,CD177 过表达能显著增强 Treg 细胞在体外的跨内皮迁移。 结论 这些结果表明,CD177 水平较高的 Treg 细胞表现出更强的活化状态和跨内皮迁移能力。我们的研究结果表明,CD177 可作为免疫治疗靶点,过表达 CD177 可提高嵌合抗原受体 T(CAR-T)细胞疗法的疗效。
{"title":"CD177 drives the transendothelial migration of Treg cells enriched in human colorectal cancer","authors":"Shouyu Ke,&nbsp;Yi Lei,&nbsp;Yixian Guo,&nbsp;Feng Xie,&nbsp;Yimeng Yu,&nbsp;Haigang Geng,&nbsp;Yiqing Zhong,&nbsp;Danhua Xu,&nbsp;Xu Liu,&nbsp;Fengrong Yu,&nbsp;Xiang Xia,&nbsp;Zizhen Zhang,&nbsp;Chunchao Zhu,&nbsp;Wei Ling,&nbsp;Bin Li,&nbsp;Wenyi Zhao","doi":"10.1002/cti2.1506","DOIUrl":"https://doi.org/10.1002/cti2.1506","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Regulatory T (Treg) cells regulate immunity in autoimmune diseases and cancers. However, immunotherapies that target tumor-infiltrating Treg cells often induce unwanted immune responses and tissue inflammation. Our research focussed on exploring the expression pattern of CD177 in tumor-infiltrating Treg cells with the aim of identifying a potential target that can enhance immunotherapy effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Single-cell RNA sequencing (scRNA-seq) data and survival data were obtained from public databases. Twenty-one colorectal cancer patient samples, including fresh tumor tissues, peritumoral tissues and peripheral blood mononuclear cells (PBMCs), were analysed using flow cytometry. The transendothelial activity of CD177<sup>+</sup> Treg cells was substantiated using <i>in vitro</i> experiments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ScRNA-seq and flow cytometry results indicated that CD177 was exclusively expressed in intratumoral Treg cells. CD177<sup>+</sup> Treg cells exhibited greater activation status and expressed elevated Treg cell canonical markers and immune checkpoint molecules than CD177<sup>−</sup> Treg cells. We further discovered that both intratumoral CD177<sup>+</sup> Treg cells and CD177-overexpressing induced Treg (iTreg) cells had lower levels of PD-1 than their CD177<sup>−</sup> counterparts. Moreover, CD177 overexpression significantly enhanced the transendothelial migration of Treg cells <i>in vitro</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These results demonstrated that Treg cells with higher CD177 levels exhibited an enhanced activation status and transendothelial migration capacity. Our findings suggest that CD177 may serve as an immunotherapeutic target and that overexpression of CD177 may improve the efficacy of chimeric antigen receptor T (CAR-T) cell therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 4","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140541096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models 利用机器学习模型通过外周血免疫分型鉴定包涵体肌炎的独特免疫特征
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-04-03 DOI: 10.1002/cti2.1504
Emily McLeish, Anuradha Sooda, Nataliya Slater, Kelly Beer, Ian Cooper, Frank L Mastaglia, Merrilee Needham, Jerome D Coudert

Objective

Inclusion body myositis (IBM) is a progressive late-onset muscle disease characterised by preferential weakness of quadriceps femoris and finger flexors, with elusive causes involving immune, degenerative, genetic and age-related factors. Overlapping with normal muscle ageing makes diagnosis and prognosis problematic.

Methods

We characterised peripheral blood leucocytes in 81 IBM patients and 45 healthy controls using flow cytometry. Using a random forest classifier, we identified immune changes in IBM compared to HC. K-means clustering and the random forest one-versus-rest model classified patients into three immunophenotypic clusters. Functional outcome measures including mTUG, 2MWT, IBM-FRS, EAT-10, knee extension and grip strength were assessed across clusters.

Results

The random forest model achieved a 94% AUC ROC with 82.76% specificity and 100% sensitivity. Significant differences were found in IBM patients, including increased CD8+ T-bet+ cells, CD4+ T cells skewed towards a Th1 phenotype and altered γδ T cell repertoire with a reduced proportion of Vγ9+Vδ2+ cells. IBM patients formed three clusters: (i) activated and inflammatory CD8+ and CD4+ T-cell profile and the highest proportion of anti-cN1A-positive patients in cluster 1; (ii) limited inflammation in cluster 2; (iii) highly differentiated, pro-inflammatory T-cell profile in cluster 3. Additionally, no significant differences in patients' age and gender were detected between immunophenotype clusters; however, worsening trends were detected with several functional outcomes.

Conclusion

These findings unveil distinct immune profiles in IBM, shedding light on underlying pathological mechanisms for potential immunoregulatory therapeutic development.

目的 包涵体肌炎(IBM)是一种渐进性晚发肌肉疾病,以股四头肌和手指屈肌无力为特征,病因难以捉摸,涉及免疫、退行性、遗传和年龄相关因素。该病与正常肌肉老化重叠,因此诊断和预后存在问题。 方法 我们使用流式细胞术鉴定了 81 名 IBM 患者和 45 名健康对照者的外周血白细胞。使用随机森林分类器,我们确定了 IBM 与 HC 相比的免疫变化。K-means 聚类和随机森林单对单模型将患者分为三个免疫表型群。对不同群组的功能结果进行评估,包括 mTUG、2MWT、IBM-FRS、EAT-10、膝关节伸展和握力。 结果 随机森林模型的 AUC ROC 为 94%,特异性为 82.76%,灵敏度为 100%。在 IBM 患者中发现了显著差异,包括 CD8+ T-bet+ 细胞增加、CD4+ T 细胞偏向 Th1 表型、γδ T 细胞群发生改变,Vγ9+Vδ2+ 细胞比例降低。IBM 患者形成了三个群:(i) 活化和炎症性 CD8+ 和 CD4+ T 细胞谱,抗 N1A 阳性患者比例最高的是第 1 群;(ii) 局限性炎症的是第 2 群;(iii) 高分化、促炎症性 T 细胞谱的是第 3 群。此外,免疫表型群组之间在患者年龄和性别方面没有发现明显差异;但在几种功能结果方面发现了恶化趋势。 结论 这些发现揭示了 IBM 患者不同的免疫特征,为潜在免疫调节疗法的开发揭示了潜在的病理机制。
{"title":"Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models","authors":"Emily McLeish,&nbsp;Anuradha Sooda,&nbsp;Nataliya Slater,&nbsp;Kelly Beer,&nbsp;Ian Cooper,&nbsp;Frank L Mastaglia,&nbsp;Merrilee Needham,&nbsp;Jerome D Coudert","doi":"10.1002/cti2.1504","DOIUrl":"https://doi.org/10.1002/cti2.1504","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Inclusion body myositis (IBM) is a progressive late-onset muscle disease characterised by preferential weakness of quadriceps femoris and finger flexors, with elusive causes involving immune, degenerative, genetic and age-related factors. Overlapping with normal muscle ageing makes diagnosis and prognosis problematic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We characterised peripheral blood leucocytes in 81 IBM patients and 45 healthy controls using flow cytometry. Using a random forest classifier, we identified immune changes in IBM compared to HC. K-means clustering and the random forest one-versus-rest model classified patients into three immunophenotypic clusters. Functional outcome measures including mTUG, 2MWT, IBM-FRS, EAT-10, knee extension and grip strength were assessed across clusters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The random forest model achieved a 94% AUC ROC with 82.76% specificity and 100% sensitivity. Significant differences were found in IBM patients, including increased CD8<sup>+</sup> T-bet<sup>+</sup> cells, CD4<sup>+</sup> T cells skewed towards a Th1 phenotype and altered γδ T cell repertoire with a reduced proportion of Vγ9<sup>+</sup>Vδ2<sup>+</sup> cells. IBM patients formed three clusters: (i) activated and inflammatory CD8<sup>+</sup> and CD4<sup>+</sup> T-cell profile and the highest proportion of anti-cN1A-positive patients in cluster 1; (ii) limited inflammation in cluster 2; (iii) highly differentiated, pro-inflammatory T-cell profile in cluster 3. Additionally, no significant differences in patients' age and gender were detected between immunophenotype clusters; however, worsening trends were detected with several functional outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings unveil distinct immune profiles in IBM, shedding light on underlying pathological mechanisms for potential immunoregulatory therapeutic development.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 4","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1504","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway 组蛋白去乙酰化酶抑制剂的协同整合显然能通过NKG2D途径提高细胞因子诱导的多发性骨髓瘤杀伤细胞的效率
IF 5.8 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-03-25 DOI: 10.1002/cti2.1500
Jingjing Pu, Amit Sharma, Ting Liu, Jian Hou, Ingo GH Schmidt-Wolf

Objectives

The rapid recognition of epigenetic manipulation's potential in restricting cancer cell capabilities spurred translational initiatives, including histone deacetylase inhibitors (HDACis). Clinical trials on multiple myeloma (MM) demonstrated substantial benefits of HDACis, coupled with promising outcomes from cytokine-induced killer cell (CIK) immunotherapy. Intriguingly, the unexplored synergy of HDACis and CIK cell immunotherapy in MM prompted our study.

Methods

We examined clinically relevant HDACis (panobinostat/LBH589 and romidepsin) alongside CIK cells derived from peripheral blood mononuclear cells across diverse MM cell lines (U266, RPMI8226, OPM-2 and NCI-H929). Utilising various in vitro methodologies, we investigated how HDACis enhance CIK cell lysis of myeloma cells through NKG2D/NKG2D ligand interactions.

Results

The results of our analysis indicated several key findings. (1) Enhanced cytotoxicity of CIK cells in MM cells when combined with HDACis. (2) Significant increase in apoptosis, suggesting HDACis and CIK may together enhance apoptotic effects in specific MM cell lines. (3) Elevated IFN-γ secretion and alterations in granzyme B secretion because of the independent activity of HDACis. (4) Notably, HDACis increased the expression of MICA/B and ULBP2, crucial for inducing antitumor cytotoxicity of NKT cells. Validation through NKG2D receptor blocking in CIK cells with a purified mouse antihuman NKG2D antibody further supported our findings.

Conclusions

Our analyses provide sufficient evidence to consider this clinically forgotten instance (HDACis-CIK cell combination) as a therapeutic priority for MM treatment. Furthermore, we suggest that NKG2D/NKG2D-ligand interactions activating NK/NKT cells may contribute to enhanced myeloma cell lysis in response to HDACis treatment by CIK cells.

目的 人们迅速认识到表观遗传操作在限制癌细胞能力方面的潜力,这推动了包括组蛋白去乙酰化酶抑制剂(HDACis)在内的转化项目的开展。对多发性骨髓瘤(MM)的临床试验表明,HDACis 具有显著疗效,细胞因子诱导的杀伤细胞(CIK)免疫疗法也取得了令人鼓舞的成果。耐人寻味的是,HDACis 和 CIK 细胞免疫疗法在 MM 中的协同作用尚未被探索,这促使我们开展了这项研究。 方法 我们研究了与临床相关的 HDACis(panobinostat/LBH589 和 romidepsin)以及来自不同 MM 细胞系(U266、RPMI8226、OPM-2 和 NCI-H929)外周血单核细胞的 CIK 细胞。利用各种体外方法,我们研究了 HDACis 如何通过 NKG2D/NKG2D 配体的相互作用增强 CIK 细胞对骨髓瘤细胞的溶解。 结果 我们的分析结果表明了几个重要发现。(1)与 HDACis 结合使用时,CIK 细胞对 MM 细胞的细胞毒性增强。(2)细胞凋亡显著增加,表明 HDACis 和 CIK 可共同增强特定 MM 细胞系的细胞凋亡效应。(3)由于 HDACis 的独立活性,IFN-γ 分泌增加,颗粒酶 B 分泌发生变化。(4)值得注意的是,HDACis 增加了对诱导 NKT 细胞抗肿瘤细胞毒性至关重要的 MICA/B 和 ULBP2 的表达。用纯化的小鼠抗人 NKG2D 抗体阻断 CIK 细胞中的 NKG2D 受体进一步证实了我们的发现。 结论 我们的分析提供了足够的证据,可将这一临床上被遗忘的实例(HDACis-CIK 细胞组合)视为 MM 治疗的优先选择。此外,我们还发现,激活 NK/NKT 细胞的 NKG2D/NKG2D 配体相互作用可能有助于增强 CIK 细胞对 HDACis 治疗的骨髓瘤细胞裂解反应。
{"title":"Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway","authors":"Jingjing Pu,&nbsp;Amit Sharma,&nbsp;Ting Liu,&nbsp;Jian Hou,&nbsp;Ingo GH Schmidt-Wolf","doi":"10.1002/cti2.1500","DOIUrl":"https://doi.org/10.1002/cti2.1500","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The rapid recognition of epigenetic manipulation's potential in restricting cancer cell capabilities spurred translational initiatives, including histone deacetylase inhibitors (HDACis). Clinical trials on multiple myeloma (MM) demonstrated substantial benefits of HDACis, coupled with promising outcomes from cytokine-induced killer cell (CIK) immunotherapy. Intriguingly, the unexplored synergy of HDACis and CIK cell immunotherapy in MM prompted our study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined clinically relevant HDACis (panobinostat/LBH589 and romidepsin) alongside CIK cells derived from peripheral blood mononuclear cells across diverse MM cell lines (U266, RPMI8226, OPM-2 and NCI-H929). Utilising various <i>in vitro</i> methodologies, we investigated how HDACis enhance CIK cell lysis of myeloma cells through NKG2D/NKG2D ligand interactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The results of our analysis indicated several key findings. (1) Enhanced cytotoxicity of CIK cells in MM cells when combined with HDACis. (2) Significant increase in apoptosis, suggesting HDACis and CIK may together enhance apoptotic effects in specific MM cell lines. (3) Elevated IFN-γ secretion and alterations in granzyme B secretion because of the independent activity of HDACis. (4) Notably, HDACis increased the expression of MICA/B and ULBP2, crucial for inducing antitumor cytotoxicity of NKT cells. Validation through NKG2D receptor blocking in CIK cells with a purified mouse antihuman NKG2D antibody further supported our findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our analyses provide sufficient evidence to consider this clinically forgotten instance (HDACis-CIK cell combination) as a therapeutic priority for MM treatment. Furthermore, we suggest that NKG2D/NKG2D-ligand interactions activating NK/NKT cells may contribute to enhanced myeloma cell lysis in response to HDACis treatment by CIK cells.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 3","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1500","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140209573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1